Liver cancer:Targeted future options

查看全文 作　　者：Andreas [1]Pircher;Michael [2]Medinger;Joachim [3]Drevs

机构地区：[1]Department for Hematology and Oncology,Medical University Innsbruck,Anichstr.35,Innsbruck 6020 Austria;[2]Hematology Department,University Hospital Basel,Petersgraben 4,Basel 4031,Switzerland;[3]Department for Internal Medicine,Hematology and Oncology,Gemeinschaftskrankenhaus Herdecke,Gerhard-Kienle-Weg 4,Herdecke 58313,Germany

出　　处：《World Journal of Hepatology》索引2011年第3卷第2期,共7页

摘　　要：Hepatocellular carcinoma(HCC)has a poor prognosis an d systemic chemotherapies have disappointing results.The increasing knowledge of the molecular biolog y of HCC has resulted in novel targets,with the vascular endothelial growth factor and epidermal growth factor receptor(EGFR)-related pathways being of special interest.New blood vessel formation(angiogenesis)is essential for the growth of solid tumors.Anti-angiogenic strategies have become an important therapeutic modality for solid tumors.Several agents targeting angiogenesis-related pathways have entered clinical trials or have been already approved for the treatment of solid tumors.These include monoclonal antibodies,receptor tyrosine kinase inhibitors and immunomodulatory drugs.HCC is a highly vascular tumor,and angiogenesis is be-lieved to play an important role in its development and progression.This review summarizes recent advances in the basic understanding of the role of angiogenesis in HCC as well as clinical trials with novel therapeutic approaches targeting angiogenesis and EGFR-related pathways. 关键词：Angiogenesis EPIDERMAL GROWTH FACTOR receptor Hepatocellular carcinoma TARGETED therapy Vascular ENDOTHELIAL GROWTH FACTOR

相关文献

参考文献（58）
引证文献（8）
耦合文献（29）

参考文献(58)

引证文献(8)

耦合文献(29)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Liver cancer:Targeted future options

参考文献(58)

引证文献(8)

耦合文献(29)

用户提示